Home / Health / Merck Drug Shows Promise Against Eye Disease
Merck Drug Shows Promise Against Eye Disease
24 Sep
Summary
- Merck's drug met its main goal in a mid- to late-stage trial.
- The drug, remigromig, was tested in adults with a serious eye condition.
- Results will be presented at the American Academy of Ophthalmology meeting.
Merck reported on September 24, 2026, a significant advancement in its drug development pipeline. The company's investigational medication, remigromig, achieved its primary endpoint in a pivotal mid- to late-stage clinical trial. This study focused on adult patients diagnosed with diabetic macular edema, a severe condition affecting the retina.
Diabetic macular edema leads to swelling and fluid accumulation in the macula, the central portion of the retina. This condition poses a substantial risk of vision loss, including blindness. Merck's remigromig demonstrated non-inferiority when compared to the established treatment, ranibizumab, in the trial.
The pharmaceutical giant confirmed that the detailed findings from this trial will be shared during the annual meeting of the American Academy of Ophthalmology. This upcoming presentation is anticipated to offer further insights into the drug's potential impact on patients battling this sight-threatening disease.
